Firm Secures Preliminary Injunction on Behalf of Eli Lilly in Prescription Rebate Fraud Litigation
On June 9, 2026, Patterson Belknap secured a preliminary injunction on behalf of the firm's client, Eli Lilly and Co. ("Eli Lilly"), in a litigation alleging that the defendants caused Eli Lilly to pay more than $200 million in fraudulent rebates.
The suit was brought against DrugPlace, Inc. ("DrugPlace") and several related entities and individuals in May 2026, alleging that the defendants claimed to have provided prescription drug coverage for tens of thousands of members of two national churches, but in fact neither the healthcare plans nor the patients existed.
The U.S. District Court for the Southern District of Florida granted Eli Lilly's preliminary injunction, as agreed upon by DrugPlace and its related entities. The ruling restricts defendants from submitting rebate claims for Eli Lilly medications without providing additional documentation about the prescription and payment. It also prevents defendants from destroying any materials related to the purchase and distribution of any Eli Lilly medication and initiates expedited discovery immediately.
To read press from Law360, click here.